Arcutis Biotherapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how the company performed in Q2 2026, helping investors understand if the business is growing or shrinking.
Leadership changes affect how well a company runs; investors watch for experience and stability in key positions.
Board members oversee company decisions; new directors with biotech experience can bring valuable expertise and leadership.
Annual votes show shareholders support management; approving the auditor ensures honest financial reporting.
Q1 earnings reveal whether the company is on track and help investors compare performance to previous periods.
Annual results show total 2025 revenue and losses, giving the clearest picture of yearly business performance.
Year-end earnings update confirms annual performance and provides guidance for investors evaluating the company.
Stocky reads Arcutis Biotherapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Arcutis Biotherapeutics, Inc.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Reports second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.